blonanserin has been researched along with clozapine in 4 studies
Studies (blonanserin) | Trials (blonanserin) | Recent Studies (post-2010) (blonanserin) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
---|---|---|---|---|---|
121 | 21 | 93 | 9,691 | 747 | 3,148 |
Protein | Taxonomy | blonanserin (IC50) | clozapine (IC50) |
---|---|---|---|
Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
D | Rattus norvegicus (Norway rat) | 1.066 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
D | Bos taurus (cattle) | 4.09 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Furukawa, K; Hino, K; Karasawa, T; Kurumiya, S; Noda, Y; Ochi, Y; Oka, M; Une, T | 1 |
Fukuda, A; Matsuno, T; Matsuo, T; Motomura, H; Shoge, T; Tashiro, N; Tatebayashi, H; Yokota, K | 1 |
Arima, H; Hamada, Y; Nakao, M; Noda, Y; Oiso, Y; Tsubai, T; Yoshimi, A | 1 |
Hashimoto, N; Ishikawa, S; Ito, YM; Kusumi, I; Okubo, R; Sato, N; Sawagashira, R; Yamamura, R | 1 |
4 other study(ies) available for blonanserin and clozapine
Article | Year |
---|---|
Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Biogenic Monoamines; Clozapine; Dogs; Dopamine D2 Receptor Antagonists; Guinea Pigs; Haloperidol; Macaca fascicularis; Male; Mice; Mice, Inbred Strains; Neurotransmitter Uptake Inhibitors; Piperazines; Piperidines; Prosencephalon; Radioligand Assay; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists; Spiperone; Tritium | 1993 |
The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Chloride Channel Agonists; Chloride Channels; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Synergism; gamma-Aminobutyric Acid; Ganglia, Spinal; Haloperidol; Incidence; Membrane Potentials; Piperazines; Piperidines; Quetiapine Fumarate; Rats; Rats, Wistar; Seizures | 2002 |
Effects of clozapine on adipokine secretions/productions and lipid droplets in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Antipsychotic Agents; Cell Survival; Clozapine; Leptin; Lipid Droplets; Mice; Piperazines; Piperidines | 2017 |
The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiepins; Female; Haloperidol; Humans; Hyperglycemia; Incidence; Japan; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Schizophrenia | 2022 |